Pediatric transplantation · 2025
Surgical Strategies for Hepatoblastoma Involving Four Liver Sectors, Look Back to Look Forward: Lessons From a Single-Center Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uchida Hajime, Sakamoto Seisuke, Hattori Noriaki, Kojima Masato, Abdelbaky Mohamed Aly, Degawa Kazuki, Kato Hirotaka, Komine Ryuji, Yanagi Yusuke, Fukuda Akinari, Shioda Yoko, Kiyotani Chikako, Matsumoto Kimikazu, Yoneda Akihiro, Haga Chiduko, Yoshioka Takako, Miyazaki Osamu, Nosaka Shunsuke, Kasahara Mureo
Аннотация
BACKGROUND: Liver transplantation (LT) has been recommended for hepatoblastoma (HB) involving all four liver sectors at diagnosis (PRETEXT IV). However, recent studies question the universal indication for primary LT in PRETEXT IV HB.
METHODS: We reviewed 32 PRETEXT IV HB patients treated at our center from February 2007 to July 2024. A multidisciplinary team reassessed surgical resectability to evaluate treatment strategies for PRETEXT IV HB.
RESULTS: Of 32 patients, 28 (87.5%) underwent LT, while 4 (12.5%) underwent liver resection (LR). Median follow-up was 4.6 years (IQR 2.3-8.5). The tumor, which was deemed radiologically resectable before surgery, was found pathologically unresectable in two LT patients: viable tumor microembolism at sites where the tumor was present at diagnosis in one patient and severe tumor ossification close to the major vascular system in one patient. Four patients with tumor thrombus, unresectable radiologically, were pathologically resectable using LR with extracorporeal circulation. Among the four patients undergoing LR, two patients eventually received LT. One had a recurrence at the initial tumor site, and the other developed cirrhosis post-LR. Surgical complications occurred in three LT patients and one LR patient. No complications related to long-term immunosuppression have been observed in LT patients. However, one LT patient developed portal hypertension due to chronic rejection and is awaiting a deceased donor LT. One LT patient died due to recurrence.
CONCLUSION: Despite uncertainties about long-term LT outcomes, LT remains the preferred strategy for safely achieving complete resection in PRETEXT IV HB patients.
METHODS: We reviewed 32 PRETEXT IV HB patients treated at our center from February 2007 to July 2024. A multidisciplinary team reassessed surgical resectability to evaluate treatment strategies for PRETEXT IV HB.
RESULTS: Of 32 patients, 28 (87.5%) underwent LT, while 4 (12.5%) underwent liver resection (LR). Median follow-up was 4.6 years (IQR 2.3-8.5). The tumor, which was deemed radiologically resectable before surgery, was found pathologically unresectable in two LT patients: viable tumor microembolism at sites where the tumor was present at diagnosis in one patient and severe tumor ossification close to the major vascular system in one patient. Four patients with tumor thrombus, unresectable radiologically, were pathologically resectable using LR with extracorporeal circulation. Among the four patients undergoing LR, two patients eventually received LT. One had a recurrence at the initial tumor site, and the other developed cirrhosis post-LR. Surgical complications occurred in three LT patients and one LR patient. No complications related to long-term immunosuppression have been observed in LT patients. However, one LT patient developed portal hypertension due to chronic rejection and is awaiting a deceased donor LT. One LT patient died due to recurrence.
CONCLUSION: Despite uncertainties about long-term LT outcomes, LT remains the preferred strategy for safely achieving complete resection in PRETEXT IV HB patients.